Deep Track Capital
Latest statistics and disclosures from Deep Track Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are GH, IONS, CYTK, AKRO, APLS, and represent 31.15% of Deep Track Capital's stock portfolio.
- Added to shares of these 10 stocks: TARS (+$74M), EXAS (+$55M), Lb Pharmaceuticals (+$53M), AKRO (+$46M), CYTK (+$36M), PCVX (+$31M), QURE (+$28M), DYN (+$25M), APLS (+$23M), MBX (+$17M).
- Started 12 new stock positions in XFOR, QURE, ACAD, CRMD, GMAB, PEPG, DYN, Imagenebio, TNGX, Lb Pharmaceuticals. BMRN, EXAS.
- Reduced shares in these 10 stocks: INSM (-$176M), PTGX (-$102M), IONS (-$71M), RARE (-$49M), DNTH (-$42M), MTSR (-$31M), TECX (-$28M), OCUL (-$28M), ABVX (-$27M), GPCR (-$26M).
- Sold out of its positions in ABVX, IVVD, SYRE, BCYC, CNTA, DNTH, IKNA, INSM, INO, KRRO. MTSR, NVAX, OKUR, PLRX, RAPP, SRPT, SEPN, TECX, RARE, UPB, MRUS.
- Deep Track Capital was a net seller of stock by $-325M.
- Deep Track Capital has $3.6B in assets under management (AUM), dropping by 14.92%.
- Central Index Key (CIK): 0001856083
Tip: Access up to 7 years of quarterly data
Positions held by Deep Track Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Deep Track Capital
Deep Track Capital holds 56 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Guardant Health (GH) | 7.2 | $260M | -2% | 4.2M | 62.48 |
|
| Ionis Pharmaceuticals (IONS) | 7.0 | $249M | -22% | 3.8M | 65.42 |
|
| Cytokinetics Com New (CYTK) | 6.6 | $236M | +17% | 4.3M | 54.96 |
|
| Akero Therapeutics (AKRO) | 5.3 | $190M | +31% | 4.0M | 47.48 |
|
| Apellis Pharmaceuticals (APLS) | 5.1 | $181M | +14% | 8.0M | 22.63 |
|
| Tarsus Pharmaceuticals (TARS) | 5.0 | $178M | +71% | 3.0M | 59.43 |
|
| Immunovant (IMVT) | 4.4 | $157M | +2% | 9.7M | 16.12 |
|
| Dynavax Technologies Corp Com New (DVAX) | 4.4 | $156M | -11% | 16M | 9.93 |
|
| Ocular Therapeutix (OCUL) | 3.9 | $140M | -16% | 12M | 11.69 |
|
| 89bio (ETNB) | 3.8 | $138M | 9.4M | 14.70 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 3.3 | $118M | -17% | 4.2M | 28.00 |
|
| Miragen Therapeutics (VRDN) | 3.2 | $116M | 5.4M | 21.58 |
|
|
| Protagonist Therapeutics (PTGX) | 3.2 | $114M | -47% | 1.7M | 66.43 |
|
| Axsome Therapeutics (AXSM) | 3.1 | $109M | +12% | 900k | 121.45 |
|
| Vaxcyte (PCVX) | 3.0 | $108M | +39% | 3.0M | 36.02 |
|
| Maze Therapeatics (MAZE) | 2.9 | $102M | 3.9M | 25.93 |
|
|
| Immunocore Hldgs Ads (IMCR) | 1.8 | $65M | 1.8M | 36.33 |
|
|
| Bridgebio Pharma (BBIO) | 1.7 | $62M | +33% | 1.2M | 51.94 |
|
| Geron Corporation (GERN) | 1.6 | $56M | -4% | 41M | 1.37 |
|
| Terns Pharmaceuticals (TERN) | 1.6 | $56M | 7.5M | 7.51 |
|
|
| Nurix Therapeutics (NRIX) | 1.6 | $56M | 6.1M | 9.24 |
|
|
| Mbx Biosciences (MBX) | 1.5 | $55M | +43% | 3.2M | 17.50 |
|
| EXACT Sciences Corporation (EXAS) | 1.5 | $55M | NEW | 1.0M | 54.71 |
|
| Lb Pharmaceuticals Com Shs | 1.5 | $53M | NEW | 3.4M | 15.79 |
|
| Celldex Therapeutics Com New (CLDX) | 1.4 | $52M | 2.0M | 25.87 |
|
|
| Oruka Therapeutics (ORKA) | 1.4 | $51M | +38% | 2.7M | 19.23 |
|
| Xenon Pharmaceuticals (XENE) | 1.3 | $48M | -11% | 1.2M | 40.15 |
|
| Compass Pathways Sponsored Ads (CMPS) | 1.3 | $45M | -10% | 7.9M | 5.73 |
|
| Biosante Pharmaceuticals (ANIP) | 1.2 | $41M | -35% | 450k | 91.60 |
|
| Bicara Therapeutics (BCAX) | 1.1 | $38M | 2.4M | 15.79 |
|
|
| Olema Pharmaceuticals (OLMA) | 0.9 | $34M | 3.5M | 9.79 |
|
|
| Cidara Therapeutics Com New (CDTX) | 0.8 | $29M | +20% | 300k | 95.76 |
|
| Uniqure Nv SHS (QURE) | 0.8 | $28M | NEW | 483k | 58.37 |
|
| Dyne Therapeutics (DYN) | 0.7 | $25M | NEW | 2.0M | 12.65 |
|
| Jade Biosciences Com New (JBIO) | 0.5 | $20M | -9% | 2.3M | 8.63 |
|
| Rapt Therapeutics Com New (RAPT) | 0.5 | $19M | 751k | 25.79 |
|
|
| Gh Research Ordinary Shares (GHRS) | 0.5 | $18M | -37% | 1.3M | 14.30 |
|
| Mind Medicine Mindmed Com New (MNMD) | 0.5 | $18M | -40% | 1.5M | 11.79 |
|
| Engene Holdings (ENGN) | 0.4 | $15M | -50% | 2.2M | 6.83 |
|
| Genmab A/s Sponsored Ads (GMAB) | 0.4 | $15M | NEW | 481k | 30.67 |
|
| Tango Therapeutics (TNGX) | 0.3 | $12M | NEW | 1.5M | 8.40 |
|
| Context Therapeutics (CNTX) | 0.2 | $7.2M | 7.4M | 0.97 |
|
|
| Imagenebio | 0.2 | $7.2M | NEW | 879k | 8.15 |
|
| Xencor (XNCR) | 0.2 | $6.4M | 549k | 11.73 |
|
|
| Cybin Com New (CYBN) | 0.2 | $5.9M | -34% | 1.0M | 5.89 |
|
| Cormedix Inc cormedix (CRMD) | 0.2 | $5.8M | NEW | 500k | 11.63 |
|
| Pepgen (PEPG) | 0.2 | $5.5M | NEW | 1.2M | 4.62 |
|
| Crescent Biopharma (CBIO) | 0.2 | $5.4M | 454k | 11.89 |
|
|
| Aligos Therapeutics Com New (ALGS) | 0.1 | $4.4M | 444k | 9.80 |
|
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.1 | $4.2M | -84% | 2.6M | 1.63 |
|
| X4 Pharmaceuticals (XFOR) | 0.1 | $3.8M | NEW | 1.1M | 3.42 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.1 | $2.2M | NEW | 105k | 21.34 |
|
| Avalo Therapeutics Com New (AVTX) | 0.1 | $1.8M | -74% | 145k | 12.71 |
|
| BioMarin Pharmaceutical (BMRN) | 0.0 | $1.3M | NEW | 25k | 54.16 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.0 | $1.1M | -85% | 259k | 4.33 |
|
| Eliem Therapeutics (CLYM) | 0.0 | $1.0M | -50% | 510k | 2.01 |
|
Past Filings by Deep Track Capital
SEC 13F filings are viewable for Deep Track Capital going back to 2021
- Deep Track Capital 2025 Q3 filed Nov. 14, 2025
- Deep Track Capital 2025 Q2 filed Aug. 14, 2025
- Deep Track Capital 2025 Q1 filed May 15, 2025
- Deep Track Capital 2024 Q4 filed Feb. 14, 2025
- Deep Track Capital 2024 Q3 filed Nov. 14, 2024
- Deep Track Capital 2024 Q2 filed Aug. 14, 2024
- Deep Track Capital 2024 Q1 filed May 15, 2024
- Deep Track Capital 2023 Q4 filed Feb. 14, 2024
- Deep Track Capital 2023 Q3 filed Nov. 14, 2023
- Deep Track Capital 2023 Q2 restated filed Sept. 6, 2023
- Deep Track Capital 2023 Q2 filed Aug. 14, 2023
- Deep Track Capital 2023 Q1 filed May 15, 2023
- Deep Track Capital 2022 Q4 filed Feb. 14, 2023
- Deep Track Capital 2022 Q3 filed Nov. 14, 2022
- Deep Track Capital 2022 Q2 filed Aug. 12, 2022
- Deep Track Capital 2022 Q1 filed May 16, 2022